HSP90 inhibitors: multi-targeted antitumor effects and novel combinatorial therapeutic approaches in cancer therapy

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Tumor resistance necessitates advanced combinatorial anticancer therapies over single-molecule inhibition.
• Heat shock protein 90 (HSP90) is a crucial chaperone protein implicated in essential cellular functions and malignant transformation.
• Numerous oncogenic client proteins associate with HSP90, contributing to cancer development.

Purpose of the Study:

• To review the effects of HSP90 inhibition in cancer treatment.
• To elucidate the mechanistic basis for HSP90 inhibition's oncogenic toxicity and selectivity.
• To discuss the progress of HSP90 inhibitors in single and combinatorial cancer therapies.

Main Methods:

• Review of preclinical and clinical data on HSP90 inhibitors.
• Analysis of the mechanism of action of HSP90 inhibitors, including ATP-binding site mimicry.
• Exploration of HSP90 client protein interactions and degradation pathways.

Main Results:

• HSP90 inhibitors demonstrate promise in various cancer models.
• Evidence suggests potential for tumor-selective cytotoxicity.
• HSP90 inhibitors may enhance sensitivity to chemotherapy and radiotherapy.

Conclusions:

• HSP90 inhibitors represent a viable strategy for combinatorial anticancer therapy.
• Targeting HSP90 effectively suppresses multiple oncogenic pathways.
• Further research into HSP90 inhibitors holds significant therapeutic potential for cancer treatment.